S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96

ASLAN Pharmaceuticals Stock Forecast, Price & News

+0.07 (+13.73%)
(As of 07/5/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
369,215 shs
Average Volume
319,372 shs
Market Capitalization
$40.46 million
P/E Ratio
Dividend Yield
Price Target

ASLAN Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
992.0% Upside
$6.33 Price Target
Short Interest
2.03% of Float Sold Short
Dividend Strength
News Sentiment
Insider Trading
Proj. Earnings Growth
From ($0.66) to ($0.89) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.90 out of 5 stars

Medical Sector

623rd out of 1,426 stocks

Pharmaceutical Preparations Industry

301st out of 682 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive ASLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ASLAN Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ASLAN Pharmaceuticals logo

About ASLAN Pharmaceuticals (NASDAQ:ASLN) Stock

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.

ASLN Stock News Headlines

ASLAN Pharmaceuticals GAAP EPS of -$0.03
Aslan Pharmaceuticals Ltd. (ASLN)
Aslan Pharmaceuticals Ltd (6497)
ASLAN (ASLN) Starts Phase IIb Study in Atopic Dermatitis
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$3 million
Book Value
$0.82 per share


Free Float
Market Cap
$40.46 million
Not Optionable

ASLAN Pharmaceuticals Frequently Asked Questions

Should I buy or sell ASLAN Pharmaceuticals stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ASLAN Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ASLAN Pharmaceuticals stock.
View analyst ratings for ASLAN Pharmaceuticals
or view top-rated stocks.

What is ASLAN Pharmaceuticals' stock price forecast for 2022?

4 brokers have issued 1-year price objectives for ASLAN Pharmaceuticals' shares. Their ASLN stock forecasts range from $3.00 to $8.00. On average, they expect ASLAN Pharmaceuticals' stock price to reach $6.33 in the next year. This suggests a possible upside of 992.0% from the stock's current price.
View analysts' price targets for ASLAN Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has ASLAN Pharmaceuticals' stock performed in 2022?

ASLAN Pharmaceuticals' stock was trading at $1.12 on January 1st, 2022. Since then, ASLN shares have decreased by 48.2% and is now trading at $0.58.
View the best growth stocks for 2022 here

When is ASLAN Pharmaceuticals' next earnings date?

ASLAN Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 5th 2022.
View our earnings forecast for ASLAN Pharmaceuticals

How were ASLAN Pharmaceuticals' earnings last quarter?

ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) posted its earnings results on Wednesday, April, 27th. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by $0.02.
View ASLAN Pharmaceuticals' earnings history

Who are ASLAN Pharmaceuticals' key executives?

ASLAN Pharmaceuticals' management team includes the following people:
  • Dr. Carl Alan Jason Morton Firth EMBA, Ph.D., Founder, CEO & Exec. Director (Age 49)
  • Mr. Kiran Kumar Asarpota, COO & Head of Fin. (Age 43)
  • Mr. Ben Goodger, Gen. Counsel (Age 59)
  • Mr. Stephen Doyle, Chief Bus. Officer (Age 49)
  • Charlie Hsu, Investor Relations Director
  • Chi-Chin Wang, IR & Corp. Devel. Director
  • Dr. Alexandre Kaoukhov M.D., Chief Medical Officer (Age 48)

What other stocks do shareholders of ASLAN Pharmaceuticals own?

When did ASLAN Pharmaceuticals IPO?

(ASLN) raised $60 million in an IPO on Friday, May 4th 2018. The company issued 7,500,000 shares at a price of $8.05 per share. Leerink Partners and Piper Jaffray acted as the underwriters for the IPO and BTIG, H.C. Wainwright and CLSA were co-managers.

What is ASLAN Pharmaceuticals' stock symbol?

ASLAN Pharmaceuticals trades on the NASDAQ under the ticker symbol "ASLN."

How do I buy shares of ASLAN Pharmaceuticals?

Shares of ASLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ASLAN Pharmaceuticals' stock price today?

One share of ASLN stock can currently be purchased for approximately $0.58.

How much money does ASLAN Pharmaceuticals make?

ASLAN Pharmaceuticals (NASDAQ:ASLN) has a market capitalization of $40.46 million and generates $3 million in revenue each year. The company earns $-31,320,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis.

How many employees does ASLAN Pharmaceuticals have?

ASLAN Pharmaceuticals employs 18 workers across the globe.

How can I contact ASLAN Pharmaceuticals?

ASLAN Pharmaceuticals' mailing address is 83 CLEMENCEAU AVENUE 12-03 UE SQUARE, SINGAPORE U0, 239920. The official website for ASLAN Pharmaceuticals is www.aslanpharma.com. The company can be reached via phone at 65-6222-4235, via email at investor@aslanpharma.com, or via fax at 65-6225-2419.

This page (NASDAQ:ASLN) was last updated on 7/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.